Payman Darouian joined Karyopharm in January 2021 and is responsible for all marketing efforts for XPOVIO.
Prior to joining Karyopharm, he spent more than 17 years in a variety of commercial leadership roles, predominately in the oncology space, including at Novartis where Payman served as the Executive Director and Global Brand Lead for Targeted Lung Cancer Therapies and also led commercial strategy for their Solid Tumor and Immuno-Oncology business. Prior to Novartis, Payman helped lead worldwide commercialization of Opdivo® for the treatment of head and neck cancer at Bristol Myers Squibb. Finally, while at Sanofi, Payman held numerous marketing leadership roles over an eight year period supporting key oncology brands, including Jevtana® and Eloxatin®.
Payman holds a PharmD from the Albany College of Pharmacy and a BS from the University of Massachusetts, Amherst.